Narrative review / 2016
A consensus statement reports that soy isoflavones reduce menopausal hot flushes and demonstrate a favorable safety profile.
This consensus statement examines evidence on isoflavones for managing menopausal vasomotor complaints. Practically all adequately designed clinical trials supported isoflavone supplementation for reducing hot flushes. An EFSA risk assessment concluded that human data indicate no suspected harm to the mammary gland, uterus, or thyroid gland, with safety established for intakes up to 150 mg per day for at least 3 years. High intake was also reported to have preventive effects regarding breast cancer and potential benefits during treatment with tamoxifen or anastrozole.
- Study type
- Consensus statement / narrative review
- Who was studied
- Menopausal women and individuals with breast cancer
- What was measured
- Menopausal vasomotor complaints (hot flushes) and safety outcomes
THE PAPER
Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints.
Schmidt M, Arjomand-Wölkart K, Birkhäuser MH, Genazzani AR, Gruber DM, Huber J, Kölbl H, Kreft S, Leodolter S, Linsberger D, Metka M, Simoncini T, Vrabic Dezman L. Gynecol Endocrinol, 2016.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.